A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: Efficacy on clinical signs and impact on the burden of illness

Dominique Bremond-Gignac, Riadh Messaoud, Sihem Lazreg, Claude Speeg-Schatz, Didier Renault, Frédéric Chiambaretta, A. Harrtani, T. Kaercher, M. Khairallah, B. Kocyla, B. Lorenz, B. Mortemousque, J. Murta, H. Nezzar, P. Nucci, J. Salgado-Borges, C. Tataru, M. Tatineanu, L. Voinea

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To compare the efficacy of azithromycin 1.5% versus tobramycin 0.3% eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen. Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5% was administered as 1 drop twice daily for 3 days, and tobramycin 0.3% as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days. Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P

Original languageEnglish
Pages (from-to)725-732
Number of pages8
JournalClinical Ophthalmology
Volume9
DOIs
Publication statusPublished - Apr 20 2015

Keywords

  • Acceptability
  • Azithromycin
  • Bacterial conjunctivitis
  • Children
  • Compliance
  • QOL
  • Topical antibiotics

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: Efficacy on clinical signs and impact on the burden of illness'. Together they form a unique fingerprint.

Cite this